This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Paul Carter, PhD
Genentech Fellow, Department of Antibody Engineering at Genentech, Inc.

Profile

Dr. Paul Carter is a Genentech Fellow in the Antibody Engineering Department at Genentech, Inc. His research passion is the quest for breakthrough antibody-based therapeutics that transform the lives of patients. His research interests include making currently intractable targets druggable with antibodies - pursuit of the ‘high-hanging fruit’. He co-initiated the humanization of antibodies at Genentech with a novel and patentable method. This technology has been utilized for the discovery of 9 approved antibody products that have been used to treat millions of patients worldwide. Paul and collaborators created ‘knobs-into-holes’ technology widely used in generating bispecific antibodies. He also developed a common light chain technology used by others in generating bispecific antibodies including one approved product. He invented technology for high-titer expression of antibody Fab fragments in E. coli used for one approved antibody product. Paul has authored or co-authored 117+ scientific publications that together have been cited 20,000+ times. He is an inventor or co-inventor on 48+ issued US patents and 60+ published US patent applications. He has co-organized 18+ international conferences on antibody engineering and antibody therapeutics. He has delivered 119+ conference presentations and invited lectures including 12+ keynote presentations. Paul received a B.A. in Natural Sciences from Cambridge University and his Ph.D. under Sir Greg Winter, Ph.D. at the MRC Laboratory of Molecular Biology in Cambridge. He was a Postdoctoral Fellow with Dr. Jim Wells at Genentech. Paul has 34+ years of biotechnology experience including at Genentech, Immunex, Amgen, Seattle Genetics and VLST. His professional experience includes heading the postdoctoral programs at Genentech, Immunex and Amgen.

Agenda Sessions

  • Engineering Bispecific Antibodies as Therapeutics: Utilizing Intrinsic Heavy/Light Chain Pairing Preferences and Mitigating High Viscosity

    11:15am
  • Inducible Activation of Antibodies to Enhance Therapeutic Index

    3:30pm
  • SESSION TITLE: Inducible Activation of Antibodies to Enhance Therapeutic Index SESSION CHAIR:

    On Demand